Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/sarcoma/volume-2015/614736/figures/614736.fig.002a.svgz" name="614736.fig.002a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Correlation of overall survival with immune response</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/sarcoma/volume-2015/614736/figures/614736.fig.002b.svgz" name="614736.fig.002b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Correlation of progression-free survival with immune response</td></tr></table>

<div>The eighteen patients who received neoadjuvant radiation and DC vaccine were divided into two groups based on their immune response (positive and negative) and then correlated with the overall survival in days and progression free survival.</div>

Sarcoma

fig2

Figure 2

Figure 2: Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma 